The RT-QuIC for alpha-synuclein amplification is a promising tool proven to identify patients with MCI at DLB’s prodromal stage compared to unimpaired controls, with 95% sensitivity of and 96% specificity. This evidence concerns the gene SNCA and Lewy body dementia.